Related Experiment Video
Updated: May 10, 2026

Enrichment of Native and Recombinant Extracellular Vesicles of Mycobacteria
Published on: December 8, 2023
Immunogenicity of Pasteurella multocida and Mannheimia haemolytica outer membrane vesicles
Sandro Roier1, Judith C Fenninger, Deborah R Leitner
1Institute of Molecular Biosciences, University of Graz, Humboldtstraße 50, A-8010 Graz, Austria.
Abstract:
Pasteurella multocida is able to cause disease in humans and in a wide range of animal hosts, including fowl cholera in birds, atrophic rhinitis in pigs, and snuffles in rabbits. Together with Mannheimia haemolytica, P. multocida also represents a major bacterial causative agent of bovine respiratory disease (BRD), which is one of the most important causes for economic losses for the cattle backgrounding and feedlot industry. Commercially available vaccines only partially prevent infections caused by P. multocida and M. haemolytica. Thus, this study characterized the immunogenicity of P. multocida and M. haemolytica outer membrane vesicles (OMVs) upon intranasal immunization of BALB/c mice. Enzyme-linked immunosorbent assays (ELISA) revealed that OMVs derived from P. multocida or M. haemolytica are able to induce robust humoral and mucosal immune responses against the respective donor strain. In addition, also significant cross-immunogenic potential was observed for both OMV types. Colonization studies showed that a potential protective immune response against P. multocida is not only achieved by immunization with P. multocida OMVs, but also by immunization with OMVs derived from M. haemolytica. Immunoblot and immunoprecipitation analyses demonstrated that M. haemolytica OMVs induce a more complex immune response compared to P. multocida OMVs. The outer membrane proteins OmpA, OmpH, and P6 were identified as the three major immunogenic proteins of P. multocida OMVs. Amongst others, the serotype 1-specific antigen, an uncharacterized outer membrane protein, as well as the outer membrane proteins P2 and OmpA were found to be the most important antigens of M. haemolytica OMVs. These findings are useful for the future development of broad-spectrum OMV based vaccines against BRD and other infections caused by P. multocida or M. haemolytica.
Insights
Outer membrane vesicles (OMVs) from Pasteurella multocida and Mannheimia haemolytica induce strong immune responses in mice. These OMVs show potential for developing broad-spectrum vaccines against bovine respiratory disease (BRD) and other infections.
Area of Science:
- Veterinary immunology
- Bacteriology
- Vaccine development
Background:
- Pasteurella multocida and Mannheimia haemolytica cause significant diseases in animals, including bovine respiratory disease (BRD).
- Current vaccines offer limited protection against P. multocida and M. haemolytica infections.
- There is a need for improved vaccines against these economically important pathogens.
Purpose of the Study:
- To characterize the immunogenicity of P. multocida and M. haemolytica outer membrane vesicles (OMVs).
- To evaluate the potential of OMVs for developing cross-protective vaccines against BRD.
Main Methods:
- Intranasal immunization of BALB/c mice with P. multocida and M. haemolytica OMVs.
- Enzyme-linked immunosorbent assays (ELISA) to assess humoral and mucosal immune responses.
- Colonization studies, immunoblot, and immunoprecipitation analyses to identify immunogenic antigens.
Main Results:
- OMVs from both bacteria induced robust homologous immune responses.
- Significant cross-immunogenicity was observed between P. multocida and M. haemolytica OMVs.
- M. haemolytica OMVs elicited a more complex immune response than P. multocida OMVs.
- Key immunogenic proteins were identified for both P. multocida (OmpA, OmpH, P6) and M. haemolytica (serotype 1-specific antigen, P2, OmpA).
Conclusions:
- P. multocida and M. haemolytica OMVs are potent immunogens.
- OMVs can induce cross-protective immunity, offering a promising strategy for BRD vaccine development.
- Identification of key antigens will aid in designing next-generation OMV-based vaccines.
More Related Videos
08:07A "Plug-And-Display" Nanoparticle Vaccine Platform Based on Outer Membrane Vesicles Displaying SARS-CoV-2 Receptor-Binding Domain
Published on: July 25, 2022
06:57Adjuvant Activity of Mycobacterium paratuberculosis in Enhancing the Immunogenicity of Autoantigens During Experimental Autoimmune Encephalomyelitis
Published on: May 12, 2023